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LETTER TO THE EDITORLow-Dose Foscarnet
Preemptive Therapy for
Cytomegalovirus Viremia after
Haploidentical Bone Marrow
Transplantation
The use of haploidentical hematopoietic stem cell
transplantation (haplo-HSCT) has increased steadily
since its introduction by Powles et al. [1]. Although
successful hematopoietic engraftment and control of
acute graft-versus-host disease (aGVHD) through
transplantation of mega-dose granulocyte colony-
stimulating factor (G-CSF)–primed bone marrow
grafts have been reported, immune reconstruction in
recipients is usually delayed [2-5]. This might result
from the use of an intensive conditioning regimen
and a combination of several immunosuppressive
agents in haplo-HSCT, resulting in a high rate of in-
fections after transplantation. Among these infections,
cytomegalovirus (CMV) is a major cause of morbidity
and mortality. Prophylactic ganciclovir, either alone
[6] or in combination with foscarnet [7], has been em-
pirically used to prevent the development of systemic
CMV infections. This approach is limited by the risk
of treatment-associated neutropenia and/or renal
toxicity, however. We report a preemptive therapy
protocol designed to control CMV viremia after
haplo-HSCT.
This study comprised 54 patients who underwent
haplo-HSCT according to protocols described previ-
ously [2,4,5]. All of the patients and donors were nega-
tive for CMV-PP65 antigenemia detected with the
CMV Brite reagent kit (Biotest Diagnostics, Denville,
NJ). Once hematopoietic engraftment was achieved, pe-
ripheral blood samples were collected, and CMV pp65–
positive cells were measured up to day 100 posttrans-
plantation. For CMV infection prophylaxis, ganciclovir
10 mg/kg/day was administered starting on day 9 pre-
transplantation, followed by acyclovir 500 mg twice
daily from day 1 to day 30 posttransplantation, then
tapered to 600 mg/day orally for up to 6 months after
transplantation. If CMV pp65–positive cells were
detected, then foscarnet treatment was started at a
dose of 60 mg/kg/day, with appropriate hydration main-
tained with 1000 mL saline solution/m2 of body surface
area. During foscarnet treatment, peripheral blood cell
count, creatinine levels, and electrolyte concentrations
were monitored.CMV antigenemia occurred in 16 patients
between day 30 and day 93 (median, 54 days) after
transplantation. Among these 16 patients, 8 patients
had fever, and 1 patient had fever with nausea, vomit-
ing, and diarrhea and was diagnosed with CMV colitis.
All 16 patients tested negative for CMV pp65 within
7 to 21 days (median, 12 days) after initiation of low-
dose foscarnet therapy. In a 6- to 24-month follow-
up, 1 patient tested positive for CMV pp65 again
12 months after transplantation. After treatment with
gancyclovir, this patient was CMV pp65–negative.
The patient with CMV colitis was treated with foscar-
net 120 mg/kg/day for 2 weeks, after which the symp-
toms were controlled and the patient tested negative
for CMV pp65.
During foscarnet treatment, 5 patients reported
nausea and loss of appetite and 2 patients exhibited
slight symptoms of urethral stimulation. No patient
exhibited obvious changes in levels of electrolytes,
creatinine, leukocytes, or platelets in peripheral
blood. No patient developed irreversible renal or
marrow failure.
Based on our findings, we recommend foscarnet as
the first-line antiviral drug to prevent CMV infection
in patients undergoing haplo-HSCT, which is associ-
ated with a higher rate of CMV viremia compared with
HLA-identical HSCT. Low-dose foscarnet provides
effective preemptive therapy for CMV antigenemia
with acceptable toxicity.ACKNOWLEDGMENTS
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